Clinical cases in oncofertility

Cancer Treatment and Research

Volumn 156, Issue , 2010, Pages 55-67

  Kondapalli, Laxmi A ^a   Hong, Fanzhen ^b   Gracia, Clarisa R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLEOMYCIN; CETRORELIX; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ESTRADIOL; ESTROGEN; FOLLITROPIN; GONADOTROPIN; IFOSFAMIDE; LETROZOLE; LEUPRORELIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT FOLLITROPIN; VINBLASTINE; WARFARIN;

ADULT; ARTICLE; BREAST CANCER; CASE REPORT; CRYOPRESERVATION; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; EWING SARCOMA; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GYNECOLOGIC SURGERY; HODGKIN DISEASE; HUMAN; MENSTRUATION; ONCOLOGY; OVARIAN RESERVE; OVARIAN TRANSPOSITION; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; SPERM PRESERVATION; THROMBOSIS;

ADOLESCENT; ADULT; FEMALE; HUMANS; INFERTILITY; NEOPLASMS; ORGAN PRESERVATION; ORGAN TRANSPLANTATION; OVARY; OVULATION INDUCTION; YOUNG ADULT;

EID: 77956367470     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6518-9_5     Document Type: Article

References (70)

1. Humaidan P, et al. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online. 2005;11(6):679-84.
2. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003;9(1):77-96.
3. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90(5 Suppl): S188-93.
4. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8(6):559-77.
5. Engmann L, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84-91.
6. Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod. 2009;24(10):2389-94.
7. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod. 2000;15(9):1965-8.
8. De Jong D, et al. Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Orgalutran/Antagon) to prevent a premature LH surge: a case report. J Assist Reprod Genet. 2001;18(1):30-3.
9. Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? J Assist Reprod Genet. 2008;25(2-3): 63-6.
10. Chen C. Pregnancy after human oocyte cryopreservation. Lancet. 1986;1(8486):884-6.
11. Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2009;93(2):391-6.
12. Yang D, et al. Live birth after the transfer of human embryos developed from cryopreserved oocytes harvested before cancer treatment. Fertil Steril. 2007;87(6):1469e1-4.
13. Yoon TK, et al. Live births after vitrification of oocytes in a stimulated in vitro fertilizationembryo transfer program. Fertil Steril. 2003;79(6):1323-6.
14. Fabbri R, et al. Human oocyte cryopreservation: new perspectives regarding oocyte survival. Hum Reprod. 2001;16(3):411-6.
15. Borini A, et al. Clinical outcome of oocyte cryopreservation after slow cooling with a protocol utilizing a high sucrose concentration. Hum Reprod. 2006;21(2):512-7.
16. Van der Elst J. Oocyte freezing: here to stay? Hum Reprod Update. 2003;9(5):463-70.
17. Hsieh YY, et al. Ultrarapid cryopreservation of human embryos: experience with 1, 582 embryos. Fertil Steril. 1999;72(2):253-6.
18. Tao T, Zhang W, Del Valle A. Human oocyte cryopreservation. Curr Opin Obstet Gynecol. 2009;21(3):247-52.
19. Check JH. Advances in oocyte cryopreservation - part II: rapid cooling using vitrification. Clin Exp Obstet Gynecol. 2009;36(1):5-9.
20. Fadini R, et al. Human oocyte cryopreservation: comparison between slow and ultrarapid methods. Reprod Biomed Online. 2009;19(2):171-80.
21. Cutting R, Barlow S, Anderson R. Human oocyte cryopreservation: evidence for practice. Hum Fertil (Camb). 2009;12(3):125-36.
22. Jemal A, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
23. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-29.
24. Oktay K, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347-53.
25. Allred CD, et al. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001;61(13):5045-50.
26. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 2002;16(6):592-4.
27. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem. 1990;33(11):2933-42.
28. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431-42.
29. Oktay K, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885-90.
30. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630-5.
31. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol. 2005;23(16):3858-9.
32. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med. 2005;353(1):64-73.
33. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006;86(1):70-80.
34. Ovarian tissue and oocyte cryopreservation. Fertil Steril. 2006;86(5 Suppl 1): S142-7.
35. Kodama H, et al. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil Steril. 1996;66(3):417-24.
36. Signorello LB, et al. Female survivors of childhood cancer: preterm birth and low birth weight among their children. J Natl Cancer Inst. 2006;98(20):1453-61.
37. Aurousseau MH, et al. Risk of thromboembolism in relation to an in-vitro fertilization programme: three case reports. Hum Reprod. 1995;10(1):94-7.
38. Yinon Y, et al. Safety of IVF under anticoagulant therapy in patients at risk for thromboembolic events. Reprod Biomed Online. 2006;12(3):354-8.
39. Marhhom E, Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv. 2007;62(1):58-72.
40. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360(9):902-11.
41. Kim SS, et al. Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod. 2001;16(10):2056-60.
42. Oktay K, et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA. 2001;286(12):1490-3.
43. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update. 2004;10(3):251-66.
44. Donnez J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405-10.
45. Meirow D, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353(3):318-21.
46. Baird DT, et al. Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at -196 C. Endocrinology. 1999;140(1):462-71.
47. Radford JA, et al. Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. Lancet. 2001;357(9263):1172-5.
48. Oktay K, Sonmezer M. Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod. 2004;19(3):477-80.
49. Kim SS. Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril. 2006;85(1):1-11.
50. Forabosco A, et al. Morphometric study of the human neonatal ovary. Anat Rec. 1991;231(2):201-8.
51. Johnson J, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004;428(6979):145-50.
52. Faddy MJ, et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7(10):1342-6.
53. Chemaitilly W, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91(5):1723-8.
54. Sklar CA, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(13):890-6.
55. Hensley ML, Reichman BS. Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Crit Rev Oncol Hematol. 1998;28(2):121-8.
56. Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril. 1986;45(4):443-59.
57. Couto-Silva AC, et al. Factors affecting gonadal function after bone marrow transplantation during childhood. Bone Marrow Transplant. 2001;28(1):67-75.
58. Wallace WH, et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62(3):738-44.
59. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am. 1998;27(4):927-43.
60. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer. 1985;55(10):2364-72.
61. Wallace WH, et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ. 2001;323(7307):271-4.
62. Lie Fong S, et al. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod. 2008;23(3):674-8.
63. Larsen EC, et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab. 2003;88(11):5307-14.
64. Bath LE, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003;18(11):2368-74.
65. Giuseppe L, et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 2007;12(2):141-7.
66. van Beek RD, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab. 2007;92(10):3869-74.
67. Husseinzadeh N, et al. The preservation of ovarian function in young women undergoing pelvic radiation therapy. Gynecol Oncol. 1984;18(3):373-9.
68. Terenziani M, et al. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril. 2009;91(3):935e15-6.
69. Jenninga E, et al. Female fertility preservation: practical and ethical considerations of an underused procedure. Cancer J. 2008;14(5):333-9.
70. Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer. 1999;86(10):2138-42.